Significant changes in VEGF concentrations in patients were observed during a treatment cycle of sunitinib, which is in line with a previous report [41], in which the authors speculate that this effect is secondary to increased activity of HIF-1α, leading to treatment-related increases in tumor hypoxia. Here, HIF1A is linked to neoplasm.